Flibanserin and Female Sexual Desire.
Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women. Flibanserin is the only currently available pharmacologic treatment for HSDD. This article will provide an overview of flibanserin, including potential adverse reactions, special considerations for use, and implications for nursing practice.
College of Health Sciences, School of Nursing at the University of Massachusetts Lowell in Lowell, MA; Health Quarters in Beverly, MA.. Electronic address: heidi_fantasia@uml.edu.
Heidi Collins
HC
Fantasia
D000284:Administration, Oral; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D017277:Drug Approval; D004347:Drug Interactions; D000431:Ethanol; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007989:Libido / Q000187:drug effects*; D008099:Liver / Q000187:drug effects; D017697:Premenopause; D018490:Serotonin Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013575:Syncope / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration
D001562:Benzimidazoles; D018490:Serotonin Agents; C098107:flibanserin; D000431:Ethanol
female hypoactive sexual desire disorder; female sexual interest/arousal disorder; flibanserin